Leap or lag: left atrial appendage closure and guidelines.

Area of Science:

• Cardiology
• Medical Devices
• Thrombosis Research

Background:

• Atrial fibrillation (AF) poses a significant risk of thromboembolism, often originating from the left atrial appendage (LAA).
• Oral anticoagulants (OACs) are standard treatment but are contraindicated or poorly tolerated by some patients due to bleeding risks.
• Many patients discontinue or reduce OAC dosage, remaining vulnerable to thromboembolic events.

Purpose of the Study:

• To evaluate left atrial appendage closure (LAAC) as an alternative thromboembolism prevention strategy in AF patients.
• To assess the evidence base for LAAC compared to OACs, considering efficacy and safety.
• To examine the discrepancy between clinical practice and current professional society guidelines regarding LAAC use.

Main Methods:

• Review of clinical trials and observational data on LAAC devices for LAA thrombosis prevention.
• Comparative analysis of LAAC efficacy and safety against OAC therapy.
• Analysis of current professional society guidelines and their alignment with clinical practice.

Main Results:

• LAAC demonstrates comparable therapeutic efficacy to OACs in preventing thromboembolism from the LAA.
• A potential small increase in ischemic strokes may be associated with LAAC compared to OACs.
• Clinical practice often precedes guideline recommendations, especially for patients unsuitable for OACs.

Conclusions:

• LAAC is a viable alternative for AF patients with unacceptable bleeding risks on OACs.
• Guidelines may need stronger recommendations for LAAC in specific patient populations where OACs are not an option.
• The evidence suggests a need for updated guidelines that better reflect clinical realities and patient needs.